Drug Interactions With Direct-Acting Antivirals for Hepatitis C: Implications for HIV and Transplant Patients

Annals of Pharmacotherapy

Volumn 49, Issue 6, 2015, Pages 674-687

  Burgess, Sarah ^a   Partovi, Nilufar ^a,b   Yoshida, Eric M ^a,b   Erb, Siegfried R ^a,b   Azalgara, Vladimir Marquez ^a,b   Hussaini, Trana ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b VANCOUVER GENERAL HOSPITAL   (Canada)

Author keywords

antiretroviral; direct acting antivirals; drug interaction; hepatitis; hepatitis C; HIV; immunosuppressant; infectious diseases; pharmacokinetics; transplant

Indexed keywords

ANTIVIRUS AGENT; AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOSPORIN A; CYTOCHROME P450 1A2; CYTOCHROME P450 3A4; DACLATASVIR; DASABUVIR; DASABUVIR PLUS OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; IMMUNOSUPPRESSIVE AGENT; LEDIPASVIR; LEDIPASVIR PLUS SOFOSBUVIR; METHYLPREDNISOLONE; MULTIDRUG RESISTANCE PROTEIN; MYCOPHENOLIC ACID; OMBITASVIR; ORGANIC ANION TRANSPORTER F; PARITAPREVIR; PROTEINASE INHIBITOR; RAPAMYCIN; RITONAVIR; SIMEPREVIR; SOFOSBUVIR; TACROLIMUS; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

AWARENESS; CLINICAL TRIAL (TOPIC); DRUG MONITORING; EMBASE; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDLINE; PRIORITY JOURNAL; REVIEW; DRUG INTERACTION; HIV INFECTIONS;

ANTI-HIV AGENTS; ANTIVIRAL AGENTS; DRUG INTERACTIONS; HEPATITIS C; HIV INFECTIONS; HUMANS; IMMUNOSUPPRESSIVE AGENTS;

EID: 84930578857     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028015576180     Document Type: Review

References (67)

1. World Health Organization. Hepatitis C. http://www.who.int/mediacentre/factsheets/fs164/en/Accessed September 10, 2014.
2. Ly KN,Xing J,Klevens RM, et al.The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007.Ann Intern Med. 2012;156:271-278
3. Manns MP,Mchutchison JG,Gordon SC,Rustgi VK,Shiffman M,Reindollar R.Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.Lancet. 2001;358:958-965
4. Fried M,Shiffman M,Reddy R, et al.Pedinterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.N Engl J Med. 2002;347:975-982
5. Jacobson I,Mchutchison J,Dusheiko G, et al.Telaprevir for previously untreated chronic hepatitis C virus infection.N Engl J Med. 2011;364:2405-2416
6. Poordad F,McCone J,Bacon B,Bruno S,Manns M,Sulkowski M.Boceprevir for untreated chronic HCV genotype 1 infections.N Engl J Med. 2011;364:1195-1206
7. Bacon B,Gordon S,Lawitz E,Marcellin P,Vierling J,Zeuzem S.Boceprevir for previously treated chronic HCV genotype 1 infection.N Engl J Med. 2011;364:1207-1217
8. Zeuzem S,Andreone P,Pol S,Lawitz E,Diago M,Roberts S.Telaprevir for retreatment of HCV infection.N Engl J Med. 2011;364:2417-2428
9. Hézode C,Fontaine H,Dorival C, et al.Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC): NCT01514890.J Hepatol. 2013;59:434-441
10. AASLD/IDSA/IAS–USA. Recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org. Accessed December 20, 2014.
11. European Association for the Study of the Liver. Recommendations on treatment of hepatitis C. http://www.easl.eu/assets/application/files/easl_recommendations_hcv_2014_full.pdf. Accessed December 20, 2014.
12. Janssen Inc.Galexos (simeprevir) product monograph. http://www.janssen.ca. Accessed February 21, 2015.
13. Janssen Inc.Olysio (simeprevir) prescribing information. https://www.olysio.com/shared/product/olysio/prescribing-information.pdf. Accessed February 21, 2015.
14. Ouwerkerk-Mahadevan S,Simion A,Spittaels K,Beumont-Mauviel M.Pharmacokinetics of simeprevir (TMC435) in volunteers with moderate or severe hepatic impairment.J Hepatol. 2013;58:S365
15. Ouwerkerk-Mahadevan S,Simion A,Peeters M,Beaumont-Mauvier M.Summary of pharmacokinetic drug-drug interactions for simeprevir (TMC435), a hepatitis C virus NS3/4A inhibitor.Abstract presented at: 14th European AIDs Conference (EACS); Brussels, Belgium;.
16. Zhou S.Drugs behave as substrates, inhibitors and inducers of human cytochrome P450.Curr Drug Metab. 2008;9:310-322
17. Sekar V,Verloes R,Meyvisch P,Spittaels K,Akuma SH,De Smedt G.Evaluation of metabolic interactions for TMC435 via cytochrome P450 enzymes in healthy volunteers.J Hepatol. 2010;52:S416
18. Gilead Sciences. Sovaldi (sofosbuvir) product monograph. http://www.gilead.ca/pdf/ca/sovaldi_pm_english.pdf. Accessed February 21, 2015.
19. Rose L,Bias TE,Mathias CB,Trooskin SB,Fong JJ.Sofosbuvir: a nucleotide NS5B inhibitor for the treatment of chronic hepatitis C infection.Ann Pharmacother. 2014;48:1019-1029
20. Cornpropst M,Denning J,Clemons D, et al.The effect of renal impairment and end stage renal disease on the single-dose pharmacokinetics of PSI-7977.Abstract presented at: 47th Annual Meeting of the European Association for the Study of the Liver (EASL); Barcelona, Spain;.
21. Lawitz E,Rodriguez-Torres M,Cornpropst M, et al.The effect of hepatic impairment on the safety, pharmacokinetics, and antiviral activity of GS-7977 in hepatitis C infected subjects treated for seven days.J Hepatol. 2012;56:S445-S446
22. Afdhal N,Everson G,Calleja J, et al.Sofosbuvir and ribavirin for the treatment of chronic HCV with cirrhosis and portal hypertension with and without decompensation: early virologic response and safety.J Hepatol. 2014;60:S28
23. Foster City, CA: Gilead Sciences Inc; 2014:
24. German P,Yang J,West S,Han L,Sajwani K,Mathias A.Effect of food and acid reducing agents on the relative bioavailability and pharmacokinetics of ledipasvir/sofosbuvir fixed dose combination tablet.Abstract presented at: 15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy; Washington, DC;.
25. German P,Mathias A,Yang J, et al.The pharmacokinetics of ledipasvir, an HCV specific NS5A inhibitor in HCV-uninfected subjects with moderate and severe hepatic impairment.Hepatology. 2013;58:432A
26. Middlesex, UK: Bristol-Myers Squibb; 1-76.
27. Garimella T,Wang R,Luo W, et al.The effect of renal impairment on single-dose pharmacokinetics to daclatasvir, an HCV NS5A inhibitor.Abstract presented at: 15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy; Washington, DC;.
28. European Medicines Agency. Summary on compassionate use for daclatasvir. http://www.ema.europa.eu/docs/en_GB/document_library/Other/2014/02/WC500160499.pdf. Accessed February 21, 2015.
29. Bifano M,Sevinsky H,Persson A, et al.Single-dose pharmacokinetics of daclatasvir (DCV; BMS-790052) in subjects with hepatic impairment compared with healthy subjects.Abstract presented at: 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD); San Francisco, CA;.
30. Bifano M,Sevinsky H,Stonier M,Jiang H,Bertz R.Daclatasvir, an HCV NS5A replication complex inhibitor, has minimal effect on pharmacokinetics of midazolam, a sensitive probe for cytochrome P450 3A4.Abstract presented at: 8th International Workshop in Clinical Pharmacology of Hepatitis Therapy; Cambridge, MA;.
31. North Chicago, IL: Abbvie Corporation; 2014:
32. Khatri A,Gaultier I,Menon R, et al.Pharmacokinetics and safety of co-administered ABT-450 plus ritonavir (ABT 450/r), ABT-267 and ABT-333 as a single dose in subjects with normal hepatic function and in subjects with mild, moderate and severe hepatic impairment.Abstract presented at: 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD); Boston, MA;.
33. Menon R,Badri P,Khatri A, et al.ABT-450/ritonavir+ ombitasvir + dasabuvir: drug interactions mediated by transporters.Abstract presented at: 15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy; Washington, DC;.
34. Foisy MM,Yakiwchuk EM,Hughes CA.Induction effects of ritonavir: implications for drug interactions.Ann Pharmacother. 2008;42:1048-1059
35. Hsu A,Granneman GR,Bertz RJ,Laboratories A,Park A.Ritonavir: clinical pharmacokinetics and interactions with other anti-HIV agents.Clin Pharmacokinet. 1998;35:275-291
36. Khalili M,Vardanian AJ,Hamerski CM, et al.Management of hepatitis C-infected liver transplant recipients at large North American centres: changes in recent years.Clin Transplant. 2005;20:1-9
37. Grassi A,Ballardini G.Post-liver transplant hepatitis C virus recurrence: an unresolved thorny problem.World J Gastroenterol. 2014;20:11095-11115
38. Hesselink DA,van Schaik RHN,van der Heiden IP, et al.Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus.Clin Pharmacol Ther. 2003;74:245-254
39. Macdonald A,Scarola J,Burke JT,Zimmerman JJ.Clinical pharmacokinetics monitoring of sirolimus and therapeutic drug monitoring of sirolimus.Clin Ther. 2000;22:B101-B121
40. Ouwerkerk-Mahadevan,Simion A,Mortier S.No clinically significant interaction between the investigational HCV protease inhibitor TMC435 and the immunosuppressives cyclosporine and tacrolimus.Abstract presented at: 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD); Boston, MA;.
41. Mathias A,Cornpropst M,Clemons D, et al.No clinically significant pharmacokinetic drug-drug interactions between sofosbuvir (GS-7977) and the immunosuppressants, cyclosporine A or tacrolimus in healthy volunteers.Abstract presented at: 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD); Boston, MA;.
42. German P,Pang P,Fang L,Chung D,Mathias A.Drug-drug interaction profile of the fixed-dose combination tablet ledipasvir/sofosbuvir.Hepatology. 2014;60:1162A
43. Reddy R,Everson G,Flamm S, et al.Ledipasvir/sofosbuvir with ribavirin for the treatment of HCV in patients with post transplant recurrence: preliminary results of a prospective, multicenter study.Abstract presented at: 65th Annual Meeting of the American Association for the Study of Liver Diseases; Boston, MA;.
44. Bifano M,Adamczyk R,Hwang C,Hamza K,Marion A,Bertz R.Daclatasvir pharmacokinetics in healthy subjects: no clinically-relevant drug-drug interactions with either cyclosporine or tacrolimus.Abstract presented at: 64th Annual Meeting of the American Association for the Stufy of Liver Diseases; Washington, DC;.
45. Badri P,Cohen D,Ding B, et al.Pharmacokinetics, safety and tolerability of cyclosporine or tacrolimus following coadministration of ABT-450/r, ABT-267 and ABT-333 in healthy subjects [Abstract].World Transplantation Congress; 2014San Francisco, CA; 2014.
46. Badri P,Parikh A,Coakley E, et al.Pharmacokinetics of cyclosporine and tacrolimus, following co-administration with the direct acting antiviral combination, ABT-450/r, ombitasvir and dasabuvir, in liver transplant patients with genotype-1 HCV infection.Abstract presented at: 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD); Boston, MA;.
47. Kwo PY,Mantry PS,Coakley E, et al.An interferon-free antiviral regimen for HCV after liver transplantation.N Engl J Med. 2014;37:2375-2382
48. Penzak SR,Formentini E,Alfaro RM,Long M,Natarajan V,Kovacs J.Prednisolone pharmacokinetics in the presence and absence of ritonavir after oral prednisone administration to healthy volunteers.J Acquir Immune Defic Syndr. 2005;40:573-580
49. Barau C,Blouin P,Creput C,Taburet AM,Durrbach A,Furlan V.Effect of coadministered HIV-protease inhibitors on tacrolimus and sirolimus blood concentrations in a kidney transplant recipient.Fundam Clin Pharmacol. 2009;23:423-425
50. Frassetto LA,Browne M,Cheng A, et al.Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients.Am J Transplant. 2007;7:2816-2820
51. Alter MJ.Epidemiology of viral hepatitis and HIV co-infection.J Hepatol. 2006;44:6-9
52. Thomas DL.The challenge of hepatitis C in the HIV-infected person.Annu Rev Med. 2008;59:473-485
53. Matthews GV,Dore GJ.HIV and hepatitis C coinfection.J Gastroenterol Hepatol. 2008;23:1000-1008
54. Wilby K,Greanya E,Ford J,Yoshida E,Partovi N.A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplant patients.Ann Hepatol. 2012;11:179-185
55. Department of Health and Human Services; Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. http://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-treatment-guidelines/0.
56. Ouwerkerk-Mahadevan S,Sekar V,Peeters M,Beumont-Mauviel M.The pharmacokinetic interactions of HCV protease inhibitor TMC435 with RPV, TDF, EFV, or RAL in health volunteers.Abstract presented at: 19th Conference on Retroviruses and Opportunistic Infections (CROI); Seattle, WA;.
57. Ouwerkerk-Mahadevan S,Sekar V,Simion A,Peeters M,Beumont-Mauviel M.The pharmacokinetic interactions of the HCV protease inhibitor simeprevir (TMC435) with HIV antiretroviral agents in healthy volunteers.Abstract presented at: Infectious Diseases Society of America; Boston, MA;.
58. Dieterich D,Rockstroh J,Orkin O, et al.Simeprevir (TMC435) plus peginterferon/ribavirin in patients co-infected with HCV genotype-1 and HIV-1: primary analysis of the C212 study.Abstract presented at: 14th European AIDs Conference (EACS); Brussels, Belgium;.
59. Kirby B,Mathias A,Rossi S, et al.No clinically significant pharmacokinetic drug interactions between sofosbuvir (GS-7977) and HIV antiretrovirals Atripla (R), rilpivirine, darunavir/ritonavir, or raltegravir in healthy volunteers.Abstract presented at: 63rd Annual Meeting of the American Association for the Study of Liver Diseases; Boston, MA;.
60. Dumond JB,Vourvahis M,Rezk NL, et al.A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir.Clin Pharmacol Ther. 2010;87:735-742
61. German P,Pang P,West S,Han L,Sajwani K,Mathias A.Drug interactions between direct acting anti-HCV antivirals sofosbuvir and ledipasvir and HIV antiretrovirals.Abstract presented at: 15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy; Washington, DC;.
62. Bifano M,Hwang C,Oosterhuis B, et al.Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir.Antivir Ther. 2013;18:931-940
63. Eley T,You X,Wang R, et alHIV DART. Miami, FL: ; 2014:
64. Khatri A,Wang T,Wang H, et al.Drug-drug interactions of the direct acting antiviral regimen of ABT-450/r, ombitasvir and dasabuvir with HIV protease inhibitors.Abstract presented at: 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); Washington, DC;.
65. Khatri A,Wang T,Wang H, et al.Drug-drug interactions of the direct acting antiviral regimen of ABT-450/r, ombitasvir and dasabuvir with emtricitabine + tenofovir, raltegravir, rilpivirine and efavirenz.54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); Washington, DC;.
66. Abel S,Russell D,Taylor-Worth RJ,Ridgway CE,Muirhead GJ.Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers.Br J Clin Pharmacol. 2008;65:27-37
67. Herold C,Heinz R,Niedobitek G,Schneider T,Eg H,Schuppan D.Quantitative testing of liver function in relation to fibrosis in patients with chronic hepatitis B and C.Liver. 2001;21:260-265